Clinical outcomes of older patients with AML receiving hypomethylating agents: a large population-based study in the United States
Abstract The hypomethylating agents (HMAs) azacitidine and decitabine have been the de facto standard of care for patients with acute myeloid leukemia (AML) who are unfit for intensive therapy. Using the Surveillance, Epidemiology, and End Results-Medicare linked database, we identified 2263 older a...
Uloženo v:
| Hlavní autoři: | , , , , , , , , , , , |
|---|---|
| Médium: | Artigo |
| Jazyk: | angličtina |
| Vydáno: |
2020
|
| On-line přístup: | https://doi.org/10.1182/bloodadvances.2020001779 https://ashpublications.org/bloodadvances/article-pdf/4/10/2192/1731682/advancesadv2020001779.pdf |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!
|